In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin

References

• Cancer. Available from: https://www.who.int/health-topics/cancer#tab=tab_1. Accessed 115, 2020.
   Google Scholar
• What Is Cancer? Available from: https://training.seer.cancer.gov/disease/cancer/. Accessed 15, 2020.
   Google Scholar
• NishidaN, YanoH, NishidaT, KamuraT, KojiroM. Angiogenesis in Cancer. Vasc Health Risk Manag. 2006;2(3):213–219. doi:10.2147/vhrm.2006.2.3.21317326328
   PubMedGoogle Scholar
• AdairTH, MontaniJ-P. Angiogenesis. San Rafael, CA: Morgan & Claypool Life Sciences; 2011.
   Google Scholar
• FolkmanJ. Angiogenesis. Annu Rev Med. 2006;57:1–18. doi:10.1146/annurev.med.57.121304.13130616409133
   PubMed Web of Science ®Google Scholar
• TahergorabiZ, KhazaeiM. A review on angiogenesis and its assays. Iran J Basic Med Sci. 2012;15(6):1110.23653839
   PubMed Web of Science ®Google Scholar
• SeverR, BruggeJS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5(4):a006098. doi:10.1101/cshperspect.a00609825833940
   PubMed Web of Science ®Google Scholar
• KessenbrockK, PlaksV, WerbZ. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. doi:10.1016/j.cell.2010.03.01520371345
   PubMed Web of Science ®Google Scholar
• FerraraN, KerbelRS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–974.16355214
   PubMed Web of Science ®Google Scholar
• MafuTS, SeptemberA, ShamleyD. The potential role of angiogenesis in the development of shoulder pain, shoulder dysfunction, and lymphedema after breast cancer treatment. Cancer Manag Res. 2018;10:81–90.29391829
   PubMed Web of Science ®Google Scholar
• UcuzianAA, GassmanAA, EastAT, GreislerHP. Molecular mediators of angiogenesis. J Burn Care Res. 2010;31(1):158–175. doi:10.1097/BCR.0b013e3181c7ed8220061852
   PubMed Web of Science ®Google Scholar
• NeveA, CantatoreFP, MaruottiN, CorradoA, RibattiD. Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Biomed Res Int. 2014;2014:1–10. doi:10.1155/2014/756078
   Web of Science ®Google Scholar
• BaudinoT. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3–20. doi:10.2174/157016381266615060214431026033233
   PubMedGoogle Scholar
• PadmaVV. An overview of targeted cancer therapy. BioMedicine. 2015;5:4.25705584
   PubMedGoogle Scholar
• BarronGA, GouaM, WahleKW, BermanoG. Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation. Oncol Rep. 2017;38(3):1886–1894. doi:10.3892/or.2017.580328714000
   PubMed Web of Science ®Google Scholar
• WangZ, DabrosinC, YinX, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35(Suppl):S224–s243. doi:10.1016/j.semcancer.2015.01.00125600295
   PubMed Web of Science ®Google Scholar
• FallahA, SadeghiniaA, KahrobaH, et al. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed Pharmacother. 2019;110:775–785. doi:10.1016/j.biopha.2018.12.02230554116
   PubMed Web of Science ®Google Scholar
• JiL, WuM, LiZ. Rutacecarpine inhibits angiogenesis by targeting the VEGFR2 and VEGFR2-Mediated Akt/MTOR/p70s6k signaling pathway. Molecules. 2018;23(8):2047. doi:10.3390/molecules23082047
   PubMed Web of Science ®Google Scholar
• LuanX, GaoY-G, Guan-Y-Y, et al. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway. Toxicol Appl Pharmacol. 2014;281(1):118–124. doi:10.1016/j.taap.2014.09.00925250884
   PubMed Web of Science ®Google Scholar
• RouwkemaJ, KhademhosseiniA. Vascularization and angiogenesis in tissue engineering: beyond creating static networks. Trends Biotechnol. 2016;34(9):733–745. doi:10.1016/j.tibtech.2016.03.00227032730
   PubMed Web of Science ®Google Scholar
• García-VilasJA, QuesadaAR, MedinaMÁ. Hydroxytyrosol targets extracellular matrix remodeling by endothelial cells and inhibits both ex vivo and in vivo angiogenesis. Food Chem. 2017;221:1741–1746. doi:10.1016/j.foodchem.2016.10.11127979155
   PubMed Web of Science ®Google Scholar
• KalogrisC, GarulliC, PietrellaL, et al. Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. Biochem Pharmacol. 2014;90(3):226–234. doi:10.1016/j.bcp.2014.05.01424875448
   PubMed Web of Science ®Google Scholar
• MohammadiM, OlsenSK, IbrahimiOA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005;16(2):107–137. doi:10.1016/j.cytogfr.2005.01.00815863029
   PubMed Web of Science ®Google Scholar
• SatoTN, TozawaY, DeutschU, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376(6535):70–74. doi:10.1038/376070a07596437
   PubMed Web of Science ®Google Scholar
• TeichertM, MildeL, HolmA, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:1. doi:10.1038/ncomms1610628232747
   PubMed Web of Science ®Google Scholar
• WernerH. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene. 2011;31(22):2703–2714. doi:10.1038/onc.2011.44721963847
   PubMed Web of Science ®Google Scholar
• GrantMB, MamesRN, FitzgeraldC, EllisEA, AboufriekhaM, GuyJ. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia. 1993;36(4):282–291.7682976
   PubMed Web of Science ®Google Scholar
• SamaniAA, YakarS, LeroithD, BrodtP. The role of the igf system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28(1):20–47.16931767
   PubMed Web of Science ®Google Scholar
• SchirrmacherV. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407–419.30570109
   PubMed Web of Science ®Google Scholar
• MaedaH, KhatamiM. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11. doi:10.1186/s40169-018-0185-629541939
   PubMed Web of Science ®Google Scholar
• HuangL, ZhaoH, HuangB, ZhengC, PengW, QinL. Acanthopanax senticosus: review of botany, chemistry and pharmacology. Die Pharmazie Int J Pharm Sci. 2011;66(2):83–97.
   Google Scholar
• ParkHJ, LeeMS, LeeKT, SohnIC, HanYN, MiyamotoKI. Studies on constituents with cytotoxic activity from the stem bark of Syringa velutina. Chem Pharm Bull (Tokyo). 1999;47(7):1029–1031. doi:10.1248/cpb.47.102910434406
   PubMed Web of Science ®Google Scholar
• HerowatiR, WidodoGP. Molecular Docking studies of chemical constituents of Tinospora cordifolia on glycogen phosphorylase. Procedia Chem. 2014;13:63–68. doi:10.1016/j.proche.2014.12.007
   Google Scholar
• LeeC-H, HuangC-W, ChangP-C, et al. Reactive oxygen species mediate the chemopreventive effects of syringin in breast cancer cells. Phytomedicine. 2019;61:152844. doi:10.1016/j.phymed.2019.15284431029906
   PubMed Web of Science ®Google Scholar
• XiaN. Syringin exhibits anticancer effects in HeLa human cervical cancer cells by inducing apoptosis, cell cycle arrest and inhibition of cell migration. Bangladesh J Pharmacol. 2016;11(4):838–843. doi:10.3329/bjp.v11i4.27755
   Web of Science ®Google Scholar
• XuJP. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group: Boca Raton: CRC Press; 2016.
   Google Scholar
• YangX, YuanJ, WanJ. Cytotoxic phenolic glycosides from Boschniakia himalaica. Chem Nat Compounds. 2012;48(4):555–558. doi:10.1007/s10600-012-0308-z
   Web of Science ®Google Scholar
• MohsRC, GreigNH. Drug discovery and development: role of basic biological research. Alzheimer’s Dementia. 2017;3(4):651–657.
   Google Scholar
• LeelanandaSP, LindertS. Computational methods in drug discovery. Beilstein J Org Chem. 2016;12(1):2694–2718. doi:10.3762/bjoc.12.26728144341
   PubMed Web of Science ®Google Scholar
• MuhsinM, GrahamJ, KirkpatrickP. Gefitinib. Nat Rev Drug Discov. 2003;2(7):515–516. doi:10.1038/nrd113612841190
   PubMed Web of Science ®Google Scholar
• GrunwaldV, HidalgoM Development of the epidermal growth factor receptor inhibitor Tarceva (TM) (OSI-774). New Trends in Cancer for the 21st Century 2003, 235–246.
   Google Scholar
• WilhelmS, CarterC, LynchM, LowingerT, DumasJ, SmithRA. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–844. doi:10.1038/nrd213017016424
   PubMed Web of Science ®Google Scholar
• WoodER, TruesdaleAT, McdonaldOB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;2004(64):6652–6659. doi:10.1158/0008-5472.CAN-04-1168
   Web of Science ®Google Scholar
• JarmanM, BarrieSE, LleraJM. The 16,17-double bond is needed for irreversible inhibition of human cytochrome P450 (17 alpha) by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3 beta-ol) and related steroidal inhibitors. J Med Chem. 1998;41:5375–5381. doi:10.1021/jm981017j9876107
   PubMed Web of Science ®Google Scholar
• ButrynskiJE, D’adamoDR, HornickJL, Dal CinP, AntonescuCR, JhanwarSC. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 1727–1733;2010(363).
   Google Scholar
• CuiW, AouidateA, WangS, YuQ, LiY, YuanS. Discovering anti-cancer drugs via computational methods. Front Pharmacol. 2020;11.
   Web of Science ®Google Scholar
• KharkarPS, WarrierS, GaudRS. Reverse docking: a powerful tool for drug repositioning and drug rescue. Future Med Chem. 2014;6(3):333–342.24575968
   PubMed Web of Science ®Google Scholar
• BillonesJB. Reverse docking study unravels the potential Mycobacterium tuberculosis enzyme targets of agelasine F. Oriental J Chem. 2016;32(2):851–858. doi:10.13005/ojc/320210
   Google Scholar
• ThanekarD, DhodiJ, GawaliN, et al. Evaluation of antitumor and anti-angiogenic activity of bioactive compounds from Cinnamomum tamala: in vitro, in vivo and in silico approach. South Afr j Botany. 2016;104:6–14. doi:10.1016/j.sajb.2015.09.014
   Web of Science ®Google Scholar
• DeryuginaEI, QuigleyJP. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol. 2008;130(6):1119–1130. doi:10.1007/s00418-008-0536-219005674
   PubMed Web of Science ®Google Scholar
• NiemistoA, DunmireV, Yli-HarjaO, ZhangW, ShmulevichI. Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging. 2005;24(4):549–553. doi:10.1109/TMI.2004.83733915822812
   PubMed Web of Science ®Google Scholar
• ZamanK, RahimF, TahaM, et al. Synthesis, thymidine phosphorylase, angiogenic inhibition and molecular docking study of isoquinoline derivatives. Bioorg Chem. 2019;89:102999. doi:10.1016/j.bioorg.2019.10299931151055
   PubMed Web of Science ®Google Scholar
• TrottO, OlsonAJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.19499576
   PubMed Web of Science ®Google Scholar
• PettersenEF, GoddardTD, HuangCC, et al. System for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612. doi:10.1002/jcc.2008415264254
   PubMed Web of Science ®Google Scholar
• KufarevaI, AbagyanR. Methods of protein structure comparison. Methods Mol Biol Homol Modeling. 2011;231–257.
   Google Scholar
• MorrisGM, Lim-WilbyM. Molecular Docking. Mol Modeling Proteins. 2008;443:365–382.
   Google Scholar
• Saleh-E-InMM, RoyA, Al-MansurMA, et al. Isolation and in silico prediction of potential drug-like compounds from anethum Sowa L. Root extracts targeted towards cancer therapy. Comput Biol Chem. 2019;78:242–259.30584950
   PubMed Web of Science ®Google Scholar
• GuanL, YangH, CaiY, et al. ADMET-score–a comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm. 2019;10(1):148–157.30774861
   PubMed Web of Science ®Google Scholar
• WangJ, PengW, LiX, et al. Towards to potential 2-cyano-pyrimidines cathepsin-K inhibitors: an in silico design and screening research based on comprehensive application of quantitative structure–activity relationships, molecular docking and ADMET prediction. J Mol Struct. 2019;2019(1195):914–928. doi:10.1016/j.molstruc.2019.06.020
   Web of Science ®Google Scholar
• LipinskiCA, LombardoF, DominyBW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;23(1–3):3–25. doi:10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• VargasA, Zeisser-LabouèbeM, LangeN, GurnyR, DelieF. The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv Drug Deliv Rev. 2007;59(11):1162–1176. doi:10.1016/j.addr.2007.04.01917870202
   PubMed Web of Science ®Google Scholar
• MousaSA, YalcinM, DavisPJ. Models for assessing anti-angiogenesis agents: appraisal of current techniques. Anti-Angiogenesis Strategies Cancer Ther. 2017;21–38.
   Google Scholar
• GungorH, IlhanN, EroksuzH. The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomed Pharmacother. 2018;102:221–229. doi:10.1016/j.biopha.2018.03.06629562216
   PubMed Web of Science ®Google Scholar
• KangKB, WangTT, WoonCT, et al. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys. 2007;67(3):888–896.17293239
   PubMed Web of Science ®Google Scholar
• MandracchiaD, TripodoG, TrapaniA, et al. Inulin based micelles loaded with curcumin or celecoxib with effective anti-angiogenic activity. Eur J Pharm Sci. 2016;93:141–146. doi:10.1016/j.ejps.2016.08.02727539141
   PubMed Web of Science ®Google Scholar
• RautCP, NawrockiS, LashingerLM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther. 2004;3(12):1217–1224. doi:10.4161/cbt.3.12.122115477758
   PubMed Web of Science ®Google Scholar
• RosasC, SinningM, FerreiraA, FuenzalidaM, LemusD. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol Res. 2014;47(1):27. doi:10.1186/0717-6287-47-2725027008
   PubMed Web of Science ®Google Scholar
• VaishV, SanyalSN. Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling. Biomed Pharmacother. 2012;66(5):354–367. doi:10.1016/j.biopha.2012.01.00422397759
   PubMed Web of Science ®Google Scholar
• RoyS, KumarA, BaigMH, MasaříkM, ProvazníkI. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer’s disease. Methods. 2015;83:105–110. doi:10.1016/j.ymeth.2015.04.02125920949
   PubMed Web of Science ®Google Scholar
• BillonesJB, CarrilloMCO, OrganoVG, et al. Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosis l,d-transpeptidase 2. Drug Des Devel Ther. 2016;10:1147–1157. doi:10.2147/DDDT.S97043
   PubMed Web of Science ®Google Scholar
• BillonesJB, CarrilloMCO, OrganoVG, et al. In silico discovery and in vitro activity of inhibitors against Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (MtbBioA). Drug Des Devel Ther. 2017;11:563–574. doi:10.2147/DDDT.S119930
   PubMed Web of Science ®Google Scholar
• BillonesJB, CarrilloMCO, OrganoVG, MacalinoSJY, EmnacenIA, SyJBA. Virtual screening against Mycobacterium tuberculosis lipoate protein ligase B (MtbLipB) and in silico ADMET evaluation of top hits. Oriental J Chem. 2013;29(4):1457–1468. doi:10.13005/ojc/290423
   Google Scholar
• UyVCC, BillonesJB. Towards antituberculosis drugs: virtual screening for potential inhibitors of pantothenate synthetase of Mycobacterium tuberculosis. Philippine Sci Letters. 2012;5(2):122–130.
   Google Scholar
• YangCTM, BillonesJB. Towards antituberculosis drugs: molecular docking of curcumin and its analogues to pantothenate synthetase. Philippine J Sci. 2012;141(2):187–196.
   Google Scholar
• BillonesJB, ValleAMF. Structure-based design of inhibitors against maltosyltransferase GlgE. Oriental J Chem. 2014;30(3):1137–1145. doi:10.13005/ojc/300326
   Google Scholar
• SampacoIII, BillonesAB, BJ. Virtual screening of natural products, molecular docking and dynamics simulations on M. tuberculosis S-adenosyl-L-homocysteine hydrolase. Oriental J Chem. 2015;31(4):1859–1865.
   Google Scholar
• WengC, FuY, JiangH, ZhuangS, LiH. Binding interaction between a queen pheromone component HOB and pheromone binding protein ASP1 of apis cerana. Int J Biol Macromol. 2015;72:430–436. doi:10.1016/j.ijbiomac.2014.08.04625195542
   PubMed Web of Science ®Google Scholar
• SinghA, DeshpandeN, PramanikN, JhunjhunwalaS, RangarajanA, AtreyaHS. Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer. Sci Rep. 2018;8(1):1–8.29311619
   PubMed Web of Science ®Google Scholar
• HagnerN, JoergerM. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010;2:293.21301589
   PubMedGoogle Scholar
• AvendañoC, MenéndezJC. Antimetabolites In: Medicinal Chemistry of Anticancer Drugs. Eds. Avendaño C, Menéndez JC, Amsterdam: Elsevier; 2008:9–52.
   Google Scholar
• HobaniY, JerahA, BidwaiA. A comparative molecular docking study of curcumin and methotrexate to dihydrofolate reductase. Bioinformation. 2017;13(3):63–66. doi:10.6026/9732063001306328584445
   PubMed Web of Science ®Google Scholar
• GuerreroPA, MccartyJH. TGF-β activation and signaling in angiogenesis. Physiol Pathol Angiogenesis Signaling Mech Targeted Ther. 2017.
   Google Scholar
• GellibertF, WoolvenJ, FouchetM-H, et al. Identification of 1,5-Naphthyridine derivatives as a novel series of potent and selective TGF-β Type I receptor inhibitors. J Med Chem. 2004;47(18):4494–4506. doi:10.1021/jm040024715317461
   PubMed Web of Science ®Google Scholar
• ZhangY, ChenY, ZhangD, WangL, LuT, JiaoY. Discovery of novel potent VEGFR-2 inhibitors exerting significant antiproliferative activity against cancer cell lines. J Med Chem. 2018;61(1):140–157. doi:10.1021/acs.jmedchem.7b0109129189002
   PubMed Web of Science ®Google Scholar
• K11. 3-[(4,6-Dipyridin-4-yl-1,3,5-triazin-2-yl)amino]-4-methyl-N-[3-(trifluoromethyl)phenyl] benzamide. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/138857895. Accessed 110, 2020.
   Google Scholar
• Jabłońska-TrypućA, MatejczykM, RosochackiS. Matrix Metalloproteinases (MMPs), the Main Extracellular Matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177–183.27028474
   PubMed Web of Science ®Google Scholar
• YueB. Biology of the extracellular matrix. J Glaucoma. 2014;23.22706338
   PubMed Web of Science ®Google Scholar
• BerglinL, SarmanS, PloegIVD, et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2–deficient mice. Invest Ophthalmol Visual Sci. 2003;44(1):403. doi:10.1167/iovs.02-018012506102
   PubMed Web of Science ®Google Scholar
• ItohY, ItoA, IwataK, TanzawaK, MoriY, NagaseNH. Plasma Membrane-Bound Tissue Inhibitor of Metalloproteinases (TIMP)-2 Specifically Inhibits Matrix Metalloproteinase 2 (Gelatinase A) Activated on the Cell Surface. J Biol Chem. 1998;273(38):24360–24367. doi:10.1074/jbc.273.38.243609733724
   PubMed Web of Science ®Google Scholar
• Ohno-MatsuiK, UetamaT, YoshidaT, et al. Reduced retinal angiogenesis in MMP-2–deficient mice. Invest Ophthalmol Visual Sci. 2003;44(12):5370. doi:10.1167/iovs.03-024914638740
   PubMed Web of Science ®Google Scholar
• PfeiferA, KesslerT, SillettiS, ChereshDA, VermaIM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci. 2000;97(22):12227–12232. doi:10.1073/pnas.22039959711035804
   PubMed Web of Science ®Google Scholar
• AgrawalA, Romero-PerezD, JacobsenJA, VillarrealFJ, CohenSM. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem. 2008;3(5):812–820. doi:10.1002/cmdc.20070029018181119
   PubMed Web of Science ®Google Scholar
• AhmadA, SayedA, GinnebaughKR, et al. Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog. Am J Transl Res. 2015;7(2):298.25901198
   PubMed Web of Science ®Google Scholar
• MukherjeeA, AdhikariN, JhaT, Pentanoic AcidA. Derivative targeting Matrix Metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line. Eur J Med Chem. 2017;141:37–50. doi:10.1016/j.ejmech.2017.09.05229028530
   PubMed Web of Science ®Google Scholar
• SmithGF. Designing drugs to avoid toxicity. Prog Med Chem Progress Med Chem. 2011;50:1–47.
   PubMedGoogle Scholar
• FingletonB. MMPs as therapeutic targets—still a viable option?Semin Cell Dev Biol. 2008;19(1):61–68. doi:10.1016/j.semcdb.2007.06.00617693104
   PubMed Web of Science ®Google Scholar
• GombarVK, SilverIS, ZhaoZ. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr Top Med Chem. 2003;3(11):1205–1225. doi:10.2174/156802603345201412769701
   PubMed Web of Science ®Google Scholar
• GongX, ZhangL, JiangR, WangCD, YinXR, WanJY. Hepatoprotective effects of syringin on fulminant hepatic failure induced by D‐galactosamine and lipopolysaccharide in mice. J Appl Toxicol. 2014;34(3):265–271. doi:10.1002/jat.287623620140
   PubMed Web of Science ®Google Scholar
• LiF, ZhangN, WuQ, et al. Syringin prevents cardiac hypertrophy induced by pressure overload through the attenuation of autophagy. Int J Mol Med. 2016;39(1):199–207. doi:10.3892/ijm.2016.282427959392
   PubMed Web of Science ®Google Scholar
• KalamK, MarwickTH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900–2909. doi:10.1016/j.ejca.2013.04.03023706982
   PubMed Web of Science ®Google Scholar
• El-GamalKM, El-MorsyAM, SaadAM, EissaIH, AlswahM. Synthesis, docking, QSAR, ADMET and antimicrobial evaluation of new quinoline-3-carbonitrile derivatives as potential DNA-gyrase inhibitors. J Mol Struct. 2018;1166:15–33. doi:10.1016/j.molstruc.2018.04.010
   Web of Science ®Google Scholar
• ChungTD, TerryDB, SmithLH. In vitro and in vivo assessment of ADME and PK properties during lead selection and lead optimization–guidelines, benchmarks and rules of thumb In: Assay Guidance Manual. Eds. Markossian S, Sittampalam GS, Grossman A, et al. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2015.
   Google Scholar
• Hodge, HC, Sterner, JH. Tabulation of Toxicity Classes. American Industrial Hygiene Association Quarterly1949;10(4):93–96. doi:10.1080/00968204909344159
   Google Scholar
• KrishnanSS, SubramanianIP, SubramanianSP. Isolation, characterization of syringin, phenylpropanoid glycoside from Musa paradisiaca tepal extract and evaluation of its antidiabetic effect in streptozotocin-induced diabetic rats. Biomed Prev Nutri. 2014;4(2):105–111. doi:10.1016/j.bionut.2013.12.009
   Google Scholar